Clyde & Co guided shareholders on sale of Chronos Therapeutics to Evgen Pharma
The agreement involved upfront and deferred equity, loans and additional mid-term development milestones
Clyde & Co guided shareholders on sale of Chronos Therapeutics to Evgen Pharma The agreement involved upfront and deferred equity, loans and additional mid-term development milestones Clyde & Co has advised the majority shareholders on the sale of Chronos Therapeutics Limited to Evgen Pharma plc, a clinical stage drug development company. Chronos, a biotech company...
Clyde & Co guided shareholders on sale of Chronos Therapeutics to Evgen Pharma
The agreement involved upfront and deferred equity, loans and additional mid-term development milestones
Clyde & Co has advised the majority shareholders on the sale of Chronos Therapeutics Limited to Evgen Pharma plc, a clinical stage drug development company.
Chronos, a biotech company headquartered in Oxford, England, operates a semi-virtual research and development model to advance degenerative and behavioral brain disease therapies.
The transaction will merge Chronos’ leading drug development programs in pre-clinical neuropsychiatry, including assets within a resurgent area for Big Pharma.
Simon Gamblin, the London corporate team partner of Clyde & Co remarked, “We are delighted to have assisted in the strategic acquisition of Chronos by Evgen which, in integrating Chronos' neuropsychiatry assets, will enable former Chronos shareholders to participate in Evgen’s diversified portfolio as it positions itself for significant advancements in the sector.”
The Clyde & Co team, led by Simon Gamblin, was supported by corporate associate Reem Katifi and senior tax associate Farhad Shahidi.